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Abstract
In recent years, the incidence and severity of Clostridium difficile-
associated disease (CDAD) have increased dramatically. Begin-
ning in 2000, widespread regional outbreaks associated with a
previously uncommon hypervirulent strain of C. difficile have
occurred in North America and Europe. Most likely because of
increased toxin production as well as other virulence factors, this
epidemic strain has caused more severe and refractory disease
leading to complications, including intensive care unit admission,
colectomies, and death. Worldwide increasing use of fluoroquino-
lones and cephalosporins has likely contributed to the proliferation
of this epidemic strain, which is highly resistant to both. The elderly
have been disproportionately affected by CDAD, but C. difficile
has also recently emerged in populations previously considered to
be at low risk, including healthy outpatients and peripartum
women, although it is unknown if these cases are related to the
epidemic strain. Nevertheless, transmission within hospitals is the
major source of C. difficile acquisition, and previous or concurrent
antimicrobial use is almost universal among cases. Applying
current evidence-based strategies for management and prevention
is critically important, and clinicians should maintain an awareness
of the changing epidemiology of CDAD and take measures to
reduce the risk of disease in patients.
Background
Since the discovery of Clostridium difficile-associated disease
(CDAD) approximately 30 years ago [1,2], much progress has
been made in our understanding of the pathogenesis and
management of this infection. In recent years, however, the
epidemiology of C. difficile has changed dramatically.
Beginning in 2000, widespread regional outbreaks of C.
difficile strains involving more severe and refractory disease
have occurred, with greater numbers of complications,
colectomies, and deaths than previously described [3-6].
Since most C. difficile acquisitions occur within healthcare
settings, emphasis should be placed on implementing
evidence-based strategies for infection control and preven-
tion, early detection, and effective treatment for severe and
relapsing CDAD.
Pathogenesis and epidemiology
Toxin-producing strains of C. difficile, an anaerobic spore-
forming bacillus, cause illnesses ranging from mild diarrhea to
fulminant colitis and toxic megacolon leading to sepsis and
even death. There are two essential requirements for CDAD
to develop: exposure to antimicrobials and new acquisition of
C. difficile, although the precise timing and order of these
events is not well understood. An important third factor,
possibly relating to host susceptibility or virulence factors of
the bacterial strain, may then determine whether the clinical
outcome will be asymptomatic colonization or CDAD [7].
Acquisition of C. difficile occurs by oral ingestion of spores,
which resist the acidity of the stomach and germinate into the
vegetative form in the small intestine. Disruption of the
commensal flora of the colon, typically through exposure to
antimicrobials, allows C. difficile to flourish and produce
toxins that lead to colitis. The primary toxins produced are
toxins A and B, two large exotoxins that cause inflammation
and mucosal damage. Both toxins appear to have cytotoxic
effects through disruption of the actin cytoskeleton within
cells [8]. Although previous evidence suggested that toxin A
is the major enterotoxin, C. difficile strains that produce toxin
B but not toxin A have recently been isolated from patients
with CDAD [9].
Nearly all antimicrobials have been implicated in the
development of CDAD [10]. Certain antimicrobial classes
that are broad-spectrum and have a propensity for killing
colonic bacteria, especially cephalosporins, clindamycin, and
most recently, fluoroquinolones, may pose a greater risk for
the development of the disease. The other major risk factors
for CDAD are advanced age and hospitalization [10]. In
addition, severe underlying disease, immunocompromising
conditions, chemotherapeutic drugs, gastrointestinal surgery,
nasogastric tubes, and gastric acid suppression are pre-
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disposing factors [11,12]. Persons with normal healthy
gastrointestinal flora and the ability to mount a brisk immune
response are at lower risk for CDAD. Asymptomatic carriers
of C. difficile have been found to have high levels of IgG anti-
bodies to toxin A and have a decreased risk of developing
CDAD compared to non-carriers [13,14]. In addition, a
vigorous serum antibody response to toxin A during an initial
episode of CDAD is associated with protection against
recurrent disease [15].
Although community-acquired C. difficile is increasingly
recognized, healthcare setting transmission is the primary
mode of C. difficile acquisition. Only about 3% of healthy
adults in the community are colonized with C. difficile, com-
pared to 20-40% of hospitalized patients [16,17]. The risk of
C. difficile acquisition is also highly correlated with length of
hospital stay [18]. The incubation period of C. difficile
following acquisition has not been clearly defined. Although
one study suggested an incubation period of less than seven
days [19], there may be prolonged intervals between onset of
diarrhea and hospital discharge or cessation of antimicrobials
[20], emphasizing the need for a high level of suspicion for
CDAD in patients presenting with diarrhea in the community
following a hospital admission.
Changing epidemiology
In the last seven to eight years, the incidence and severity of
C. difficile have increased dramatically. CDAD rates in
intensive care units increased significantly from 1987 to
2001 in hospitals with greater than 500 beds [21]. In the
United States, the number of hospital discharges where
CDAD was listed as any diagnosis doubled between 2000
and 2003, with a disproportionate increase for persons aged
>64 years [22] (Figure 1). By 2003, regional reports of
CDAD outbreaks from hospitals throughout the US and in
Quebec, Canada emerged, describing severe disease
associated with greater numbers of complications, including
colectomies, treatment failures, and deaths [3-5]. In 2004,
the attributable mortality rate of nosocomial CDAD in Quebec
hospitals was 6.9% [3], compared to 1.5% among Canadian
hospitals in 1997 [23]. In the US, death certificate data
suggest mortality rates due to CDAD increased from 5.7 per
million population in 1999 to 23.7 per million in 2004 [24].
By contrast, a study in a US medical center in 1998 found no
excess mortality attributable to CDAD after adjustment for
confounding factors [25].
A hypervirulent epidemic strain of C. difficile was found to be
associated with the outbreaks in the US and Quebec and
subsequently with outbreaks in the United Kingdom and other
parts of Europe [3,4,26]. The epidemic strain has been
characterized as restriction enzyme analysis type BI, North
American Pulsed-Field Type 1 (NAP1), and PCR ribotype
027 [4,27]. Restriction enzyme analysis of the pathogenicity
locus containing the toxin and associated regulatory genes
also classifies this strain as toxinotype III, a previously
uncommon toxinotype among hospital strains [28]. The
BI/NAP1/027 strain has been found to produce 16-fold
higher concentrations of toxin A and 23-fold higher concen-
trations of toxin B in vitro [27], a finding that is most likely
related to the presence of an early frameshift mutation
identified in tcdC within the pathogenicity locus of this
epidemic strain [29], since the product of the unaltered gene
normally inhibits toxin production [30]. An 18 base pair
deletion is also present within this gene in the epidemic strain
but is downstream of the frameshift mutation and does not
alter the function of the TcdC protein [30]. Another charac-
teristic of the strain is the production of a toxin called binary
toxin, the role of which is not yet defined; however, strains
that produce the binary toxin may be associated with more
severe diarrhea [31]. The cause of the extreme virulence of
the BI/NAP1/027 strain may be a combination of increased
toxins A and B, binary toxin, or other features particular to
toxinotype III strains.
Another feature related to the proliferation of this strain is its
universal, high levels of resistance to fluoroquinolones, inclu-
ding the C-8-methoxyfluoroquinolones, moxifloxacin and
gatifloxacin [4]. Although BI/NAP1/027 isolates existed
previously, historic strains were less resistant to fluoroquino-
lones, and they were not associated with outbreaks of
disease. The emergence of this strain now is likely related to
its selective advantage in the presence of widespread
increasing use of fluoroquinolones. A similar phenomenon
was observed with the clindamycin-resistant ‘J strain’, which
caused outbreaks in the late 1980s and early 1990s [32].
In addition to strain characteristics, host factors also play a
major role in CDAD, and the elderly have been particularly
affected. In recent studies, CDAD rates, severity, and
mortality have been highest in persons >65 years of age
[3,6,22,24]. C. difficile is a significant cause of outbreaks and
non-epidemic diarrhea in nursing homes [33,34]. The
Figure 1
Rates of discharges from US short-stay hospitals of patients with
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association of CDAD with advanced age may be a result of a
weaker immune response to C. difficile or other underlying
illnesses. However, C. difficile has also recently emerged in
populations previously considered to be at low risk, including
healthy outpatients, peripartum women, children, and people
with no recent antibiotic exposure [35]. More research is
needed to determine if these cases are due to strains carry-
ing similar virulence factors to the BI/NAP1/027 strain.
Diagnosis
Early diagnosis is key to preventing complications from
severe CDAD and preventing transmission. Rapid diagnosis
depends on maintaining a high degree of clinical suspicion
for CDAD in patients with diarrhea and recent antimicrobial
exposure and hospitalization. The tissue culture cytotoxic
assay has long been considered the gold standard diagnostic
test but is limited by slow turnaround time (at least 48 hours),
work intensity, and cost [8]. The enzyme immunoassay for
detection of toxins A and B is the most commonly used test in
clinical laboratories because of its ease of use and rapidity.
Although the test is highly specific, it has a lower sensitivity
(70-87%) than the cytotoxic assay [36-39]. However, testing
two or three stool specimens can increase the yield by 10%
or more [39]. Assays that test for both toxins A and B are
required to detect toxin A-B+ strains.
The detection of C. difficile by culture is rarely performed for
diagnostic purposes because it is labor intensive and has a
slow turnaround time. However, if culture is combined with
toxin testing of the recovered isolate (so-called ‘toxigenic
culture’), it may be even more sensitive than the tissue cyto-
toxin assay [40] and offers the additional advantage of
providing isolates for strain typing to better understand
transmission dynamics in a hospital. One promising approach
is the use of the highly sensitive, albeit less specific, C.
difficile antigen assay as a screening test with a rapid
turnaround time, followed by confirmatory testing of positives
using a cytotoxin assay or toxigenic culture [41].
Treatment strategies
When initiating treatment for CDAD, the first basic principle
is to stop the offending antimicrobial(s) if possible. In one
study, 41% of patients who remained on antibiotics during
treatment of CDAD with metronidazole failed, compared to
none of those whose antibiotics were discontinued [42].
Therapy should be administered orally if possible, and
continued for at least 10 days. Anti-peristaltic agents,
including narcotics, should be avoided. For conditions such
as toxic megacolon and ileus, alternative routes, such as
administration of vancomycin enterally via a nasogastric tube
and/or directly into the colon as an enema, should be used
[43,44]. Finally, early surgical consultation may improve
survival in selected patients with fulminant CDAD [45-47].
The two primary agents used to treat CDAD are
metronidazole and oral vancomycin. Earlier randomized trials
showed equivalent response rates of greater than 90% with
either drug [48,49]. Because metronidazole is considerably
less expensive than oral vancomycin and possibly less likely
to promote the selection of vancomycin-resistant Entero-
coccus spp., practice guidelines have recommended metro-
nidazole as first-line treatment for CDAD [50,51]. However,
more recent concerns about treatment failure with metro-
nidazole, particularly in cases of severe disease, have been
raised [52,53]. In one randomized, double-blinded trial of
vancomycin versus metronidazole for CDAD, cure rates were
equivalent for mild CDAD (98% and 90% for vancomycin and
metronidazole, respectively). However, for severe disease, the
cure rate was significantly higher for vancomycin (97%) than
for metronidazole (76%) [54]. Since the majority of the cases
in this study occurred before recognition of the hypervirulent
BI/NAP1/027 epidemic strain, it is unknown whether these
findings can be generalized to the current epidemic.
However, in a recent phase 3 study comparing the efficacy of
the toxin binder tolevamer to vancomycin or metronidazole for
CDAD, vancomycin was found to be superior to
metronidazole for severe disease (defined as ≥10 bowel
movements/day, white blood cell count ≥20,001/mm3, or
severe abdominal pain due to CDAD) with a clinical success
rate of 85% for vancomycin versus 65% for metronidazole
(p = 0.04) [55]. Therefore, vancomycin may be preferred as
initial treatment for patients with risk factors for a complicated
outcome or poor response to metronidazole, such as
intensive care unit stay, low albumin level, fever, leukocytosis,
profuse diarrhea, and elevated creatinine [6,54-56].
Recommendations for treatment of CDAD based on disease
severity are given in Table 1.
Recurrent C. difficile-associated disease
Between 15% and 35% of patients with a first episode of
CDAD relapse within two months [57]. Having one recur-
rence puts patients at high risk for subsequent recurrences
[58]. Other risk factors for recurrence include older age and
decreased quality of life scores, and women appear to be
more affected than men by recurrent disease [58]. An
adequate serum immune response to toxin A during a first
episode of C. difficile provides protection from recurrence
[15]. Reinfections with different strains of C. difficile have
been found in a large proportion of recurrences, suggesting
that many can be avoided by ensuring adherence to infection
control measures [57].
The recommended treatment for a first recurrence is a
second course of the initial therapy with either metronidazole
or vancomycin. A commonly used treatment strategy for
subsequent recurrences is a prolonged, tapering course of
oral vancomycin, which may be followed by pulsed dosing
[59]. Other strategies include combination antimicrobial
therapy and efforts to restore the normal colonic flora by the
use of probiotics or stool transplants. Newer antimicrobial
agents and other adjunctive therapies for severe or relapsing
disease are discussed below.
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Several newer antibiotics have been found to have good
activity against C. difficile. Nitazoxanide, which is used for
other gastrointestinal infections, was as effective as metro-
nidazole in a randomized, double-blind study of hospitalized
patients with CDAD [60]. Rifaximin, also used for other
gastrointestinal infections, is a rifamycin-based drug that is
not absorbed and achieves high fecal drug levels. It has been
used in combination with vancomycin or as follow-up therapy
after a course of vancomycin for patients with recurrent
CDAD [61]. However, the development of rifaximin resistance
is a concern, especially when the drug is used as mono-
therapy. In addition, resistance to rifampin in C. difficile,
which accurately predicts rifaximin resistance, was found to
be common among C. difficile isolates belonging to the
epidemic BI/NAP1/027 strain in at least one institution,
possibly limiting the utility of rifaximin for treating CDAD
caused by this epidemic strain [62,63].
The investigational drug OPT-80 (difimicin) showed
promising results in treating patients with CDAD and low
rates of recurrence in a phase 2 trial [64] and is currently in
phase 3 trials comparing treatment efficacy with oral vanco-
mycin. Tolevamer, a soluble anionic polymer that binds to
toxins A and B of C. difficile, is a non-antibiotic therapy under
investigation for treatment of CDAD and was found to be
noninferior to vancomycin in treating patients with mild to
moderate CDAD in a FDA phase 2 study [65]. However,
preliminary results suggest it has failed to meet its
noninferiority end point in a recent phase 3 trial [55].
Ramoplanin, an agent previously evaluated for eradication of
vancomycin-resistant  Enterococcus spp. colonization, was
equally as effective as vancomycin in in vitro and hamster
models of CDAD [66] and compared favorably to vancomycin
for CDAD in a phase 2 clinical trial [67].
Probiotics
Adjunctive therapies for refractory disease include efforts to
replenish colonic flora with the use of orally administered
probiotics, usually Lactobacillus species or Saccharomyces
boulardii. A recent systematic review of randomized controlled
trials to evaluate the efficacy of probiotic therapies identified
only two treatment studies that showed some benefit of S.
boulardii, although the benefit was restricted to subgroups of
patients with severe or recurrent CDAD [68]. A more recent
randomized, controlled study found some benefit of a yogurt
containing Lactobacillus spp. and Streptococcus thermo-
philus in the prevention of antibiotic-associated diarrhea and
CDAD in patients over 50 years of age, although the
applicability of the study has been questioned due to highly
selective exclusion and inclusion criteria [69]. There is a
concern over the safety of probiotics in severely ill or immuno-
compromised patients with several reports of S. boulardii
fungemia [70] and less frequent reports of sepsis due to
Lactobacillus spp. [71]. In general, there is insufficient
evidence to support the routine use of probiotics to prevent
or treat CDAD. Finally, case reports and case series have
shown success with administration of donor stool or
‘synthetic stool’ (bacterial mixtures), either by nasogastric
tube or colonoscopy [72-74].
Immunomodulation
Pooled human immunoglobulin contains antitoxin IgG
antibodies capable of neutralizing C. difficile, and case
reports have described rapid responses to intravenous
immunoglobulin in patients with severe CDAD, although
randomized controlled trials are needed [75,76]. A C. difficile
toxoid vaccine has been developed and induces high level
responses of serum antitoxin A IgG in healthy volunteers [77].
Further studies are needed to determine whether the vaccine
responses confer protective immunity against CDAD and
whether adequate immune responses are achieved in the
elderly or in patients with recurrent C. difficile. Another
immune therapy approach, the use of human antitoxin A and
B monoclonal antibodies, reduced mortality in a hamster
model of CDAD [78].
A detailed review of the current status of investigational
therapies for CDAD was recently published by Miller [79].
Prevention
Transmission of C. difficile within hospitals has been
observed through time-space clustering of new cases with
identical strains and a greater risk of acquisition of C. difficile
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Table 1
Antimicrobial Treatment for C. difficile-associated disease based on disease severity
Disease classification Recommended treatment
Mild to moderate disease (mild to moderate diarrhea, leukocytosis  Metronidazole 500 mg orally 3 times/day for 10 to 14 days 
<15,000/μl)
Severe disease (fever, profuse diarrhea, abdominal pain, leukocytosis  Vancomycin 125 to 500 mg orally 4 times/day for 10 to 14 days
≥15,000/μl, elevated creatinine)
Severe disease, complicated (hypotension, shock, toxic megacolon,  Vancomycin 500 mg enterally by nasogastric tube and/or rectal enema 
ileus) 4 times/day with or without intravenous metronidazole 500 mg every 
8 hours 
Adapted using data from [6,43,44,54,56,79,92].from exposure to roommates or other patients in close
proximity who have positive cultures [17,80]. C. difficile
spores have been found to contaminate the hands of
healthcare workers and the hospital environment frequently
[17,81].
Because alcohol-based hand sanitizers do not inactivate the
spores of C. difficile, concern over their role in transmission
of  C. difficile have been raised. However, hospitals using
alcohol-based hand rubs as their primary means of hand
hygiene have not seen increases in the incidence of CDAD
associated with their introduction [82]. Due to the theoretical
advantage of hand washing over alcohol-based hand
sanitizers, hand washing with a non-antimicrobial soap or
antimicrobial soap and water should be considered after
removing gloves in the setting of a CDAD outbreak or if
ongoing transmission cannot be controlled by other
measures [83].
Patients with CDAD should be placed on contact
precautions and housed in single rooms with private bath-
rooms or, if unavailable, cohorted in rooms with other patients
with CDAD [84]. Single-use disposable or patient-dedicated
noncritical equipment should be used. Wearing gloves is one
measure that has been proven to reduce the spread of C.
difficile in hospitals [85]. Gowns and gloves should be
donned prior to entering the room of a patient with CDAD
and removed followed by hand hygiene before leaving the
room.
Although all hospital cleaning agents can inhibit the growth of
C. difficile in culture, only chlorine-containing agents
inactivate  C. difficile spores. In the most definitive study
evaluating environmental cleaning, the use of a 1:10 dilution
of a 6% hypochlorite solution for daily room cleaning of
CDAD patients in a bone marrow transplant unit decreased
the CDAD rate significantly but had no effect on units with
lower baseline CDAD rates [86]. Therefore, the use of
hypochlorite might be most effective in units where CDAD is
highly endemic. The drawbacks of hypochlorite solutions are
that most of them must be prepared fresh daily and they can
be caustic and damaging to hospital equipment.
Antimicrobial use restrictions are another potential mecha-
nism of controlling and preventing C. difficile. As with
environmental cleaning, the exact role of antimicrobial
restrictions is undefined due to the presence of confounding
factors in most studies. However, several studies support the
use of formulary restrictions promoting the use of narrow-
spectrum antibiotics to reduce the incidence of CDAD
[87-89]. Formulary substitutions of 8-methoxyfluoroquino-
lones for levofloxacin have also been proposed to control
CDAD outbreaks caused by the BI/NAP1/027 strain. While
this appeared to be effective in one study [90], it was
ineffective in another, most likely because the overall use of
fluoroquinolones in the hospital was not controlled [91].
Since resistance of the BI/NAP1/027 strain to fluoro-
quinolones is a class effect resulting in higher minimum
inhibitory concentrations (MICs) to all fluoroquinolones [4],
the incidence of disease caused by such resistant strains is
not likely to be reduced without controlling fluoroquinolone
use in general.
Conclusion
The increasing incidence and severity of CDAD in North
America and Europe present major challenges for control and
management of this disease. Continued gathering of data on
the epidemiology of C. difficile through disease surveillance
both within and outside of healthcare facilities, and on the
efficacy of prevention and treatment strategies is essential to
reduce the burden of this disease. Meanwhile, all clinicians
and especially critical care physicians should maintain
awareness of the changing epidemiology of CDAD and
undertake measures to reduce the risk of disease in their
patients.
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